1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B1DA3AD76F821ED000258711006B338A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/B1DA3AD76F821ED000258711006B338A?OpenDocument
18
19OpenDocument
203.233.242.204
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Document Excerpt: Leveraging Outcomes Data – Launch Investment and Technology in Health Economics & Outcomes Research in Oncology Products

DB Image

ID: MD-787


Features:

11 Info Graphics

8 Data Graphics

100+ Metrics

2 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".


To return to the study abstract to purchase the full study - click here.

This excerpt includes research findings and metrics from document #5687 "Leveraging Outcomes Data - Launch Investment and Technology in Health Economics & Outcomes Research in Oncology Products

Industries Profiled:
Pharmaceutical; Consumer Products; Biotech; Health Care; Laboratories; Diagnostic; Communications; Biopharmaceutical


Companies Profiled:
AbbVie; Merck Serono; Novartis; Astellas; Boehringer Ingelheim; Pfizer; Eisai; Takeda Pharmaceuticals; Ipsen; Merck Sharp & Dohme; Daiichi Sankyo; Alkem; Foundation Medicine; Sun Pharmaceutical; Karyopharm Therapeutics; Brii Biosciences; Nucleus Global; Seattle Genetics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.